NJA 004
Latest Information Update: 02 Feb 2024
At a glance
- Originator Shinobi Therapeutics
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 19 Dec 2023 NJA 004 is available for licensing as of 19 Dec 2023. https://www.shinobitx.com/
- 19 Dec 2023 Early research in Autoimmune disorders in USA (Parenteral)